Roche has announced plans to invest $50 billion into the United States in the next five years, further strengthening its already significant U.S. footprint and creating more than 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities.

The investment will include:

• Expanded and upgraded U.S. manufacturing and distribution capabilities for its innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
• A gene therapy manufacturing facility in Pennsylvania
• A new 900,000 square foot manufacturing center to support Roche’s expanding portfolio of next-generation weight loss medicines (location to be announced)
• A new manufacturing facility for continuous glucose monitoring in Indiana
• A new R&D center in Massachusetts, conducting artificial intelligence (AI) research and serving as a hub for its new cardiovascular, renal and metabolism research and development efforts
• Significant expansion and upgrading of its existing pharmaceuticals and diagnostics R&D centers in Arizona, Indiana and California

“Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the U.S.,” said Thomas Schinecker, Roche Group CEO. “We are proud of our 110-year legacy in the United States, which has been a key driver for jobs, innovation and the creation of intellectual property in the U.S., across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

Once all new and expanded manufacturing capacity comes online, Roche says it will export more medicines from the U.S. than it imports. Today, its diagnostics division already has an export surplus from the U.S. to other countries.

This news comes weeks after Johnson & Johnson announced plans to invest more than $55 billion in the U.S. over the next four years and Novartis announced plans to invest $23 billion over 5 years in U.S.-based infrastructure.